Genes in which germline mutations confer highly or moderately increased risks of cancer are called cancer predisposition genes. More than 100 of these genes have been identified, providing important scientific insights in many areas, particularly the mechanisms of cancer causation. Moreover, clinical utilization of cancer predisposition genes has had a substantial impact on diagnosis, optimized management and prevention of cancer. The recent transformative advances in DNA sequencing hold the promise of many more cancer predisposition gene discoveries, and greater and broader clinical applications. However, there is also considerable potential for incorrect inferences and inappropriate clinical applications. Realizing the promise of cancer predisposition genes for science and medicine will thus require careful navigation.
G enetic predisposition to cancer has been recognized for centuries, initially through observation of unusual familial clusterings of cancer. In 1866, neuroanatomist Paul Broca published one of the earliest reports on the subject, detailing a striking history of breast cancer in 15 members of his wife's family 1 . Broca, controversially for the time, proposed that this was evidence of hereditary predisposition to cancer. Fifty years later, biologist Theodor Boveri published his visionary theory that somatic acquisition of "particular, incorrect chromosome combinations" underlies cancer. His paper was equally prophetic about inherited predisposition to cancer, predicting it could result from "weakened resistance against the action of factors that stimulate cell division" 2 . In 1971, mathematical modelling of the epidemiology of retinoblastoma by geneticist Alfred Knudson suggested a 'two-hit' model whereby both alleles of a specific gene were required to be inactivated for retinoblastoma to occur 3 , thus echoing Boveri's predictions. In 1987, the retinoblastoma predisposition gene RB1 was discovered, and in hereditary cases one allele was mutated in the germ line with the second allele inactivated somatically 4 . There is no definitive definition of a cancer predisposition gene (CPG). For the purposes of this Review, I have restricted inclusion to those genes in which rare mutations confer high or moderate risks of cancer (greater than twofold relative risks) and to those for which at least 5% of individuals with the relevant mutations develop cancer. For most genes, both the risks and penetrance are considerably higher than these minimum criteria. Common variants conferring very small increases in risk discovered through genome-wide association studies (GWAS) are not included within this definition. Such variants are important components of the genetic architecture of cancer and are addressed in other reviews [5] [6] [7] . Through extensive literature and database evaluations, I identified 114 CPGs that form the basis of this Review ( Fig. 1 ; see Supplementary Information).
Conventionally, cancer predisposition reviews have focused on select cancers and/or sets of genes. In an era of whole-genome sequencing, information about all known CPGs is increasingly desirable in both research and clinical practice. Here, I have aspired to integrate knowledge from three decades of research to provide a distillation of key CPG characteristics. I also discuss the exciting prospects and potential pitfalls of future discoveries and clinical applications.
Discovery of CPGs
The 114 CPGs were discovered over the past 30 years through multiple strategies (Fig. 2 ). Since 1990, at least one new CPG has been identified each year, peaking in 1996, when 10 CPGs were reported [8] [9] [10] [11] [12] [13] [14] [15] [16] . Genomewide linkage analysis, an agnostic approach that allows tracking of disease-associated genomic markers in high penetrance familial clusters has been the most successful strategy, yielding 59 CPGs, mostly during the 1990s when the methodology became routine. Next-generation sequencing is leading to a new crop of CPGs being discovered through genomewide mutational analyses such as exome and genome sequencing 17, 18 . The remaining genes were identified through various candidate-based strategies. Large numbers of candidate CPGs have been proposed and investigated. For most, no association with cancer predisposition has been found. This perceived failure led to candidate-based approaches falling out of favour. However, certain strategies have proved very successful both as stand-alone discovery methods and in facilitating linkage studies. Candidates pursued as surrogates of cancer predisposition -for example distinctive cellular phenotypes such as defective DNA repair, mosaic aneuploidies or telomere shortening -have contributed to the discovery of many CPGs 9, 10, 19, 20 . Genetic-pathway candidates, that is, genes selected because they function in similar pathways to known CPGs, have also yielded new predisposition genes, particularly in colorectal, breast, ovarian and endocrine cancers [21] [22] [23] [24] [25] [26] [27] [28] . Candidate genes that have been chosen because they are somatically mutated in cancers have, perhaps surprisingly, led to the identification of only 12 CPGs [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] .
Overlap of somatic and germline cancer genes
It is interesting and instructive to consider the overlap between the known germline and tumour-mutated cancer genes. Currently, the COSMIC (Catalogue of Somatic Mutations in Cancer) database includes 468 genes that are somatically mutated in cancers 41 . Of these, 49 are also known to be CPGs. Conversely, 65 of the 114 CPGs are known to be somatically mutated. These data imply that 10% of somatically mutated cancer genes also confer susceptibility to cancer when mutated in the germ line, but that 40% of germline-mutated CPGs can also contribute to oncogenesis when mutations occur only in tumours (Fig. 3) . This apparent discrepancy is, at least in part, an artefact of different research approaches; it is common for the frequency of somatic CPG mutations to be investigated, but it is unusual for somatically mutated genes to be evaluated for their role in cancer predisposition. The latter has been exacerbated by cancer genome sequencing studies in which a key filtering step is the removal of variants that are present in normal tissue to focus attention on the potential cancer-driving mutations that are present only in the tumour 42 . Thus, it is highly likely that there is an underestimate of the overlap between somatic cancer driver mutations and germline cancer predisposing mutations, and mutual interrogation of such genes could prove to be a useful approach for identification of new cancer genes.
Overlap of high and low penetrance cancer-associated variants
One notable absentee in the successful CPG discovery strategies is identification through GWAS candidature. There are 391 known common variants that confer small increased risks of cancer 43 . The underlying causal gene or mechanism has only been identified for a small minority, but none have been shown to be sentinels of rare and higher penetrance mutations in new CPGs. Furthermore, only 15 SNPs (single nucleotide polymorphisms) are within known CPGs and none are associated with cancers that occur in carriers of rare, penetrant mutations. For example, ATM D1853N (the only exonic cancer GWAS variant in a CPG) confers a protective effect against melanoma, but it is not associated with the cancers that occur in biallelic or monoallelic ATM mutation carriers 44, 45 . Similarly, the SNP rs78378222 alters the polyadenylation signal of TP53 and is associated with various cancers, but not those that typically occur in patients with the cancer predisposition condition Li-Fraumeni syndrome, which is due to germline TP53 mutations 46 . Multiple variants in the vicinity of TERT have been associated with several different cancers, but again not those that occur in the multisystem disorder dyskeratosis congenita, which is a recessive condition due to germline exonic TERT mutations [47] [48] [49] . These data suggest the mechanisms underlying the association of rare, high penetrance alleles and common, low penetrance alleles with cancer are largely distinct. This differs from several other common, complex conditions that show considerable overlap between these components of the genetic architecture 50, 51 .
Characteristics of CPGs
The 114 genes are located throughout the genome with little evidence of chromosomal clustering (Fig. 1 ).
Inheritance and mechanisms of oncogenesis
The inheritance pattern of cancer predisposition is varied; it is autosomal dominant for 65 CPGs, autosomal recessive for 28, X-linked for 4 and Y-linked for 1. Sixteen genes cause phenotypes in both monoallelic and biallelic mutation carriers, that is, they cause autosomal dominant and autosomal recessive conditions. For half of these, the recessive condition is a more severe manifestation of the dominant condition. For example, biallelic BRCA2, PALB2, MLH1, MSH2, MSH6 and PMS2 mutation carriers have a high risk of childhood cancer, whereas monoallelic mutation carriers have an increased risk of adult cancers 52 . For other genes in which monoallelic and biallelic mutations cause clinical phenotypes, such as FH and SDHA, cancer has not been reported in biallelic mutation carriers. This may be because of early mortality from other causes.
Most CPGs act as tumour suppressor genes with mutations that abrogate their function, promoting oncogenesis. Only 11 genes predispose 
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to cancer through gain-of-function mutations. Several of these, such as RET, MET, KIT and ALK, encode kinases that are rendered constitutively active by cancer predisposing mutations 53 . Much more diversity exists in the types, functions and mechanisms of oncogenesis of CPGs that when inactivated increase the risk of cancer. Many are classic tumour suppressor genes, requiring both alleles to be inactivated, but haploinsufficiency and dominant-negative mechanisms also occur. For some genes, different mutations operate through different mechanisms and lead to distinct phenotypes 54, 55 . For many genes, the clinical phenotypes and cancer risks associated with CPG mutations are also influenced by other factors, both genetic and non-genetic.
Functions of CPGs
CPG research has directly resulted in insight into basic biological pathways and gene function. Several essential genes were first isolated because germline mutations within them predispose cancer, as is transparent in their names (for example, breast cancer 1, BRCA1; or retinoblastoma 1, RB1), which reflect the clinical phenotypes that led to their identification. The functions of these genes were only subsequently elucidated, often directly because of research into their role in cancer predisposition.
CPGs have a very broad range of functions. Many are ubiquitously expressed and participate in fundamental processes such as DNA repair and cell-cycle regulation. One of the enduring conundrums of cancer predisposition is why, and how, perturbation of universal cellular functions can cause exquisitely specific cancer phenotypes. However, some genes have organ-specific functions that are transparently related to the cancers with which they are associated. For example, mutations in SLC25A13, ABCB11, FAH, HMBS and UROD all lead to hepatic overload, liver cirrhosis and, hence, an increased risk of hepatocellular carcinoma 56 . Meaningful evaluation of the 114 CPGs for functional associations is currently precluded because so many were identified owing to their functional relationships with known CPGs. Nonetheless, some noteworthy functional networks are emerging as important in cancer predisposition, in addition to well-recognized pathways such as DNA repair. Among these are the SWI-SNF chromatin-remodelling pathway, which has been linked to rhabdoid tumours and meningiomas; the succinate dehydrogenase enzyme complex, which is associated with phaeochromocytoma and paragangliomas; and the PI(3)K-mTOR signalling pathway, which has links with several CPGs, including TSC1, TSC2, PTEN, STK11, FLCN, HRAS and TMEM127, and hence is associated with diverse cancers [57] [58] [59] .
Cancer phenotypes
It is currently estimated that around 3% of cancers are due to CPG mutations, which is equivalent to more than 300,000 cancers per year worldwide. This is an underestimate because the contribution of known genes has been poorly characterized and not all genes have been identified. The contribution to individual cancers is highly variable. The highest attribution is to childhood embryonal tumours such as retinoblastoma and pleuropulmonary blastoma which are often due to germline mutations in RB1 and DICER1, respectively 29, 60 . This simplicity is not applicable to all childhood cancers; the embryonal kidney cancer Wilms tumour is associated with several CPGs and other predisposition mechanisms, which together account for less than 5% of cases 61, 62 . At the other end of the spectrum, known CPGs make a very small contribution to some adult cancers, such as prostate and lung cancer. However, germline CPG mutations in multiple genes predispose carriers to other adult cancers such as breast, colorectal, melanoma and ovarian cancer. For some, the overall contribution of CPGs is sizeable, with around 15% of ovarian cancers, about 20% of medullary thyroid cancers and more than 30% of phaeochromocytomas due to CPG mutations [63] [64] [65] . Some CPGs preferentially predispose carriers to specific histological subtypes of a cancer. For example, BRCA1 is particularly associated with triple-negative breast cancer and serous ovarian cancer, whereas CDH1 is particularly associated with lobular breast cancer and diffuse gastric cancers 66, 67 . The genomic profiles of cancers arising in individuals with germline CPG mutations can also be distinctive; chromothripsis, which describes localized chromosomal shattering, is striking in medulloblastomas that occur in TP53 germline mutation carriers, and cancers in BRCA1 or BRCA2 mutation carriers have a characteristic mutational signature that includes substantial numbers of deletions with overlapping microhomology at the breakpoint junctions 68, 69 .
Non-cancer phenotypes
Clinical phenotypes in addition to cancer often occur in individuals with CPG mutations, with 87 CPGs being associated with non-cancer clinical features. These are often more discriminating and more common than cancer, and can be crucial to clinical diagnosis of the underlying cancer syndrome. The spectrum of additional clinical features is very broad. Skin manifestations are the most frequent and can be specific to the relevant CPG. They include hypopigmented and/or hyperpigmented areas, freckling, rashes, blistering, hypertrophy, skin tags, and nodules and/or lumps. Neurological, dysmorphic and skeletal manifestations also occur, but are usually nonspecific features such as microcephaly, macrocephaly, short stature and/or developmental delay. The proportion of CPGs associated with non-cancer clinical phenotypes is probably an overestimation of the true proportion, as identification of genes that result in a readily clinically recognizable phenotype is inevitably more tractable.
Genotype-phenotype associations
One of the illuminating outcomes of CPG research has been increased knowledge about the diversity of mutational mechanisms and their relationship with phenotype. Even superficially straightforward associations can mask profound complexity. For example, gain-of-function germline HRAS missense mutations cause enhanced MAPKK and PI(3)K signalling similar to somatic mutations 70 . However, the spectrum of germline and somatic mutations differs, and germline HRAS mutations not only predispose to cancer but also cause a multisystem disorder called Costello syndrome 71 . This condition includes distinctive facial dysmorphism and a wide range of cardiac, dermatological, musculoskeletal and developmental abnormalities. The role of HRAS in these processes, and why HRAS 
REVIEW INSIGHT
The genotype-phenotype relationships of some CPGs are extraordinarily intricate and hint at deep uncharted complexities in gene function. Most WT1 mutations predispose carriers to Wilms tumour, genitourinary abnormalities and renal dysfunction, the severity of which is influenced by the mutational type. However, intronic mutations that alter the relative abundance of WT1 isoforms cause a distinct condition, called Frasier syndrome, which includes gonadoblastoma rather than Wilms tumour, a focal-segmental nephropathy and severe gonadal dysgenesis, which can manifest as complete sex reversal 61 . TERT, which encodes telomerase, is another example. Recently, activating promoter mutations that result in increased telomerase expression were shown to predispose carriers to melanoma 72 . Monoallelic and biallelic, primarily missense TERT mutations cause dyskeratosis congenita, which is characterized by various physical abnormalities, pulmonary fibrosis, bone-marrow failure and increased incidence of acute myelogenous leukaemia and squamous carcinomas of the head and neck and anogenital region 48 . Furthermore, various common SNPs in the vicinity of TERT confer small risks of several cancers, including breast, colorectal, testicular and prostate 47, 49 . The mechanisms underlying the diversity of TERT phenotypic associations are unknown.
TGFBR1, which encodes a transmembrane serine/threonine kinase receptor, is one of the most extreme examples of genotype-phenotype diversity. Missense mutations in the kinase domain cause marfanoid vasculopathies with no increased risk of cancer. Truncating mutations in the same kinase domain, or missense mutations in the extracellular ligand-binding domain, cause a highly unusual condition called multiple self-healing squamous epithelioma. Individuals with the condition develop squamous-carcinoma-like locally invasive skin tumours that grow rapidly for a few weeks then spontaneously regress and scar 73 .
CPG cancer risks
There is a deep and widely underappreciated complexity in the risks of cancer conferred by CPG mutations. A specific CPG mutation can confer different risks of developing different cancers. Different CPG mutations can confer different risks of developing a particular cancer. A specific CPG mutation can even confer different risks of developing a particular cancer in different contexts. BRCA2 illustrates all of these scenarios. Loss-of-function BRCA2 mutations confer substantial increased lifetime risks of breast and ovarian cancer but only small increased lifetime risks of prostate and pancreatic cancer 74 . However, not all mutations confer the same risk, despite most being proteintruncating mutations predicted to result in nonsense-mediated RNA decay and thus to be functionally equivalent. Loss-of-function BRCA2 mutations in the central part of the gene confer significantly higher relative risks of ovarian cancer compared with breast cancer than mutations at either end 75 . The mechanistic basis for this highly unusual pattern is unknown. The degree of family history also impacts on the risk of cancer of BRCA2 mutations. The lifetime breast cancer risk of female BRCA2 mutation carriers with a strong family history is around 80%, but the risk is only about 45% for relatives of breast cancer cases unselected for family history 76, 77 . This reflects, at least in part, additional modifying factors within familial clusters that increase cancer risk. Some genetic and non-genetic modifying factors of BRCA2 and BRCA1 cancer risks have already been identified, although it is likely there is still much to be discovered [78] [79] [80] [81] . TP53 is another gene that has been known for more than 20 years to predispose carriers to cancer, but our knowledge of the associated cancer risks is still lamentably incomplete. All germline TP53 mutations are typically assumed to be highly penetrant, but the widely quoted cancer lifetime risks are derived from small series of highly selected cases 82 . In fact, there is strong evidence of high variability in the types and risks of cancer associated with different TP53 mutations. This is exemplified by TP53 R337H, which confers a modest 10% risk of adrenocortical cancer and is not associated with increased risks of other classic Li-Fraumeni syndrome cancers such as breast cancer or sarcoma 83 .
Clinical utility of CPGs
The identification of CPGs has had substantial clinical impact. Cancer is one of the foremost diseases for which such discoveries have transformed medical care in multiple areas, including cancer prevention.
Diagnosis and patient management
The benefits of determining whether a cancer is due to a germline CPG mutation are incontrovertible. As such, CPG testing has become standard for many genes, albeit typically only in highly selected cases. From a patient perspective, simply having a better understanding of why their cancer occurred is usually highly valued. It also provides important information that can aid diagnosis and management, for instance whether surgery should be conservative or radical. Radiotherapy and chemotherapy may also be altered. For example, platinum-based therapies are not standard treatment for breast cancer but can have utility in BRCA carriers 84, 85 . Conversely, temozolomide is unlikely to be of benefit and may actually promote neoplastic progression in MSH6 mutation carriers 86, 87 . Identifying an underlying CPG mutation also provides important prognostic information; survival is significantly better for BRCA2 mutation-positive patients with ovarian cancer but significantly worse for BRCA2 mutation-positive patients with prostate cancer 88, 89 . The likelihood of recurrence, a new primary and/or a second malignancy can all be increased in CPG mutation carriers who require ongoing review and consideration of tailored surveillance and/or risk-reducing interventions. Management of non-cancer-associated problems can also be important, for example certain WT1 mutations result in insidious renal dysfunction, which requires monitoring and early intervention.
Targeted therapies
There is intense activity in the development of tailored therapies for cancer and strategies targeting CPGs and their constituent pathways have been among the most innovative and fruitful. The rationale is to harness knowledge of the underlying cause of cancer to identify tumour-specific vulnerabilities that can be therapeutically exploited. The simplest model is in cancers caused by gain-of-function mutations, which can be directly downregulated by inhibitors such as imatinib (KIT and PDGFRA), vandetanib (RET) and foretinib (MET) [90] [91] [92] . Trying to switch on genes that have been mutationally inactivated is more challenging. A direct approach of using compounds that 'read-through' stop codons is showing some promise, as is gene therapy 93, 94 . Inhibiting a pathway member that is upregulated as a result of the CPG mutation has also had success. For example, everolimus, an mTOR inhibitor, is now approved for treatment of astrocytomas in tuberous sclerosis, and vismodegib, which inhibits the hedgehog pathway, has been found to be beneficial for basal-cell nevus syndrome patients with PTCH1 mutations 95, 96 . Perhaps, the most innovative approach has been through inducing synthetic lethality. PARP inhibitors, which cause lethality in BRCA deficient tumour cells but not normal cells with monoallelic mutations exemplify this approach, which is now being pursued for other CPGs [97] [98] [99] . Currently, these therapies are 
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still largely being evaluated in research studies and clinical trials, but there is optimism that identification of CPG mutations will increasingly lead to personalized management for patients with cancer.
Screening and prevention
An important benefit of CPG testing is being able to provide information about cancer risks to relatives. One of the unusual characteristics of CPGs is their capacity to serve as a biomarker of future disease. Identifying a CPG mutation can provide a window of opportunity to implement surveillance and/or risk-reducing measures that mitigate or prevent cancer. Naturally, the type of screening is determined by the type of cancer but most often involves imaging to detect a lesion before it presents clinically. Sometimes, a biochemical marker of risk can be measured, such as catecholamines or calcitonin in individuals who are at risk of phaeochromocytoma or thyroid cancer, respectively 100 . The presumption is that if a cancer is detected early, treatment and survival will be improved, although this has rarely been proven and for some cancers the available evidence does not suggest a benefit 101 . Prevention usually involves surgical removal of the at-risk tissue and is necessarily reserved for non-essential organs in individuals at very high risk, such as the stomach in CDH1 mutation carriers, the thyroid in RET mutation carriers and the colon in APC mutation carriers 100, 102, 103 . Chemoprevention is an attractive strategy, but to date there have been few applications. A notable exception is mismatch repair gene mutation carriers, in whom the risk of colorectal cancer is significantly reduced by daily aspirin 104 . Of equal value, although commanding much less fanfare, is the use of CPG mutation testing in identifying people who do not have a familial CPG mutation. Such individuals do not have the high cancer risk of their relatives, reducing anxiety for themselves and their offspring. They also typically do not require costly, intensive screening or preventative interventions.
Pitfalls in CPG research and clinical practice
The study of CPGs has led to tremendous scientific and medical advances of broad and lasting impact. However, the field has been hampered by incorrect interpretations of genetic data, which can have substantial negative consequences.
The first major problem is the incorrect classification of a gene as a CPG. There are, unfortunately, dozens of genes in widely-used databases such as OMIM (Online Mendelian Inheritance in Man) and HGMD (The Human Gene Mutation Database) that are designated CPGs but for which the evidence is at best uncertain. For most, interpretation of the available data strongly suggests the gene does not confer high or moderate risks of cancer. There are various reasons for these misclassifications. Until recently, the extent of human coding variation was poorly appreciated, leading to overestimation of the likely causal link between the presence of a gene variant and cancer in an individual. This problem is actually increasing with exome-sequencing studies, with many researchers failing to appreciate that rare coding variations, including putative deleterious mutations, are collectively common 105, 106 . The most widespread misconception is that the absence from the control group of a specific rare mutation that was identified in cancer cases provides evidence of causality, whereas usually it merely provides additional evidence that it is rare.
Over-extrapolation of concepts and data is a pervasive problem in CPG research and manifests in many ways. First, it is often presumed that if a gene mutation causes one cancer that any other cancer that occurs in a mutation carrier is also probably attributable to that gene, whereas frequently it will be coincidental because cancer is very common. Second, it is frequently incorrectly assumed that because one mutation class (for example, truncating mutations) predisposes carriers to cancer that variants in other classes (for example, missense mutations) are also causative, but many will be rare, innocuous variants. Third, it is commonly assumed that if some genes in a pathway are CPGs then variants in other gene members of that pathway are de facto likely to predispose carriers to cancer. Fourth, it is widely thought that cancer risks of CPG mutations are constant and can be extrapolated from one context to another, whereas many factors can influence the clinical expression of a CPG mutation.
Finally, it is often incorrectly assumed that if a variant is shown to have some kind of functional impact, this proves it is pathogenic. CPGs have multiple complex functions and the relationship between functional aberrations and clinical phenotype is typically unclear or unknown. There are very few CPG functional assays that have been validated as robust tests of clinical pathogenicity. Thus, although functional data can provide supportive evidence for pathogenicity it can very rarely serve as a substitute for robust genetic evidence.
The extent to which these presumptions lead to incorrect scientific inferences and inappropriate clinical management depends on the specific CPG and scenario. However, significant and unacceptable negative impacts can result, including unwarranted surgery in healthy individuals.
Future opportunities and challenges
The future for CPG research is very bright, both in terms of scientific discovery and clinical translation. Strong evidence from multiple sources indicates that more CPGs remain to be discovered. Exome and genome sequencing are ideally suited to their identification, although standards to ensure consistent, robust designation as a CPG are required. For familial and syndromic cancer conditions, exome sequencing methods developed for Mendelian disorders will probably be successful, and are already yielding new genes 17, 18 . As with other common, complex conditions, identification of non-syndromic genes will remain challenging, at least until it is possible to sequence, analyse and interpret data from many thousands of individuals. Innovative sample and analytical prioritization strategies, in the spirit of those used so successfully in the past will thus probably have high utility over the next few years 106 . It is also important to recognize that in this Review I have focused on germline gene mutations with high or moderate risks of cancer. Other components of the genetic architecture of cancer predisposition, such as common variants with small effects are also important and the interplay of different genes and variants is a topical field that will probably reveal new and clinically relevant insights 78, 81, 107 . It is also increasingly apparent that many other mechanisms are likely to play a part. One emerging area is the role of mosaic mutations, particularly in individuals with multiple cancers. Genetic and epigenetic cancer-predisposing post-zygotic events have been identified, for example mosaic HIF2A mutations in individuals with paraganglioma and H19 hypermethylation in children with bilateral Wilms tumour 108, 109 . More recently, mosaic PPM1D mutations associated with increased risk of ovarian and breast cancer have been reported, although the mechanism of cancer association is currently unclear 110 . Even though a considerable proportion of genetic predisposition to cancer probably resides in CPGs, the genetic architecture of cancer predisposition includes other components, many of which may be undiscovered.
Opportunities to use CPGs to improve management of patients should be vigorously pursued. This will lead to optimized, personalized care for mutation carriers and will probably provide insights of broader relevance to cancer, as exemplified by countless CPG-based discoveries of the past. The rarity of CPG mutations impedes research, and improved networks and registries of mutation carriers would greatly enhance the field. Routine integration of germline CPG testing into clinical trials will be invaluable, as will better collaborative links between somatic and germline cancer research. Probably the most important goal, which would facilitate all of the points mentioned, is to increase availability of CPG testing to patients with cancer. Next-generation sequencing makes large-scale, high-throughput CPG testing possible and affordable, but the clinical infrastructure needed to appropriately deliver such testing requires development. Various initiatives are seeking to achieve this, such as the UK Mainstreaming Cancer Genetics programme (http://www.mcgprogramme.com).
It is imperative that comprehensive evaluation of known CPGs in large patient and population series is performed so their cancer risks, clinical phenotypes, genotype-phenotype associations, genetic and non-genetic modifying factors, and contribution to cancer can be clarified. Largescale, international, integrated molecular and clinical databases and analyses will greatly facilitate these endeavours. Enthusiasm for feedback of 
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incidental findings is best tempered until these data are available. Recently, the American College of Medical Genetics issued a policy statement recommending that incidental findings in 24 CPGs should be returned to the patient, irrespective of age or specific consent 111 . This has stimulated intense debate about possible ethical and legal ramifications. However, scant attention has been given to the arguably more pressing concern of our insufficient knowledge about the clinical consequences of mutations identified opportunistically. As already discussed, there is evidence to suggest that the impact of incidental mutations may differ substantially from that of mutations detected in individuals with a clinical phenotype and thus more curation and more caution are required.
That being said, the impact of CPG mutations in the general population is of high interest and has the potential to provide health benefits and opportunities for cancer prevention. It is often assumed cancer surveillance is of intrinsic value and should automatically be instituted in CPG mutation carriers. However, for most surveillance programmes there is little or no actual evidence of an improvement in outcome. The lack of proven efficacy and the potential risks of screening, such as overdiagnosis, misdiagnosis, false positives and false negatives, are rarely discussed. The low frequency of CPG conditions makes randomized clinical surveillance trials challenging. It also leads to the misguided impression that ad hoc screening in individual CPG families is a trivial burden. In fact, instituting decades of surveillance to relatives in a single family can be a very considerable financial outlay. To implement this at the population level, which may insidiously occur as genome sequencing becomes routine, could spiral into sizeable strains on the capacity and purse of health services. This is particularly likely if individuals with rare variants of unproven pathogenicity are (inappropriately) included in enhanced surveillance programmes, as is currently often the case. To ensure consistent, appropriate and affordable management of at-risk individuals, there needs to be a grass-roots move away from reflex interventions and to application and adherence to the accepted criteria of effective screening tests 112 . In parallel, we need to invest energy in developing carefully considered and evaluated strategies that maximize the benefits of identifying people who are at increased risk of cancer. ■
